Abstract: Ultrasound-guided needle procedures require skills that are challenging to master, especially considering the need to manipulate 3-D structures while observing 2-D images (or even 3-D images). A pre-clinical assessment and training apparatus, methods, and systems are described herein. Targeting tasks require participants to contact target models designed to test various skills. Performance is compared between those with experience in ultrasound-guided medical procedures and those without experience, using at least one targeting task likely to be beneficial for assessment.
Abstract: The invention provides compositions and methods for identifying autism and autism spectrum disorders in humans. The invention also includes compositions and methods for identifying unique gene expression profiles in children with regressive autism spectrum disorder (ASD) and ileocolitis.
Abstract: The present invention relates to compounds, compositions and methods comprising nanoparticles (NP) that are based on hyaluronic acid (HLA) that have been modified with hydrophobic moieties that can entrap FASN inhibitor compounds. In one embodiment, the FASN inhibitor compounds include Orlistat. In one embodiment, the hydrophobic moieties comprise 5-?CA, Pba, or ODA, or combinations thereof. In a variation, the present invention relates to a composition comprising NPs based upon HLA, Orlistat, one or more of the hydrophobic moieties comprising 5-?CA, Pba, or ODA, and one or more of members selected from the group consisting of PEG and a dilute solution containing SDS.
Type:
Grant
Filed:
July 25, 2015
Date of Patent:
April 30, 2019
Assignee:
Wake Forest University Health Sciences
Inventors:
Aaron M. Mohs, Steve J. Kridel, Tanner K. Hill
Abstract: Medical kits and methods for performing small incision DLEK include a corneal transplantation donor tissue graft formed into an implantable and compact rolled configuration using the flexible substrate.
Abstract: In one aspect, organic thin film transistors are described herein. In some embodiments, an organic thin film transistor comprises a source terminal, a drain terminal and a gate terminal; a dielectric layer positioned between the gate terminal and the source and drain terminals; and a vibrationally-assisted drop-cast organic film comprising small molecule semiconductor in electrical communication with the source terminal and drain terminal, wherein the transistor has a carrier mobility (?eff) of at least about 1 cm2/V·s.
Type:
Grant
Filed:
January 22, 2018
Date of Patent:
April 9, 2019
Assignee:
Wake Forest University
Inventors:
Oana Diana Jurchescu, Peter James Diemer
Abstract: The disclosure relates to cyclopropyl derivatives and methods of use. In some embodiments, the disclosure relates to methods of managing medical disorders with pharmaceutical compositions disclosed herein administered to subject in need thereof. In certain embodiments, the disclosure relates to methods of managing mental disorders, mood disorders, pain, and fibromyalgia and related conditions with pharmaceutical compositions disclosed herein.
Type:
Grant
Filed:
May 3, 2016
Date of Patent:
February 19, 2019
Assignees:
Emory University, Wake Forest University Health Services
Inventors:
Huw M. L. Davies, Spandan Chennamadhavuni, Thomas J. Martin, Steven R. Childers
Abstract: The invention provides a catalyst and a method for making the catalyst. The catalyst comprises a porous carbon composite impregnated with a salt. The catalyst comprises a porous carbon composite impregnated with a salt.
Type:
Application
Filed:
June 25, 2018
Publication date:
December 27, 2018
Applicants:
UT-Battelle, LLC, Georgia Institute of Technology, Wake Forest University
Inventors:
Mariappan Paranthaman, Amit K. Naskar, Abdou Lachgar, Younan Xia, Zachary David Hood, Shiba Prasad Adhikari
Abstract: Cell tubes that can be used both for pathology collection and subsequent cell processing include a tube with a cell bed at a lower portion of the tube. The tube can include a base member that can be detachable from the tube body. The tubes can be used to form cell (cytology) blocks that incorporate the cell bed. The cell bed can be an inert cell bed of paraffin.
Abstract: The present invention provides methods and devices for predicting, preventing, detecting and/or treating seizures. In some embodiments, the present invention provides methods/devices for predicting a seizure prior to its inception, wherein the seizure is predicted based upon neuronal activity in the CA3 region of a patient's hippocampus.
Type:
Grant
Filed:
January 3, 2014
Date of Patent:
November 13, 2018
Assignee:
Wake Forest University Health Sciences
Inventors:
Mark R. Witcher, Robert E. Hampson, Sam Deadwyler, Daniel E. Couture, Gautam Popli
Abstract: The present invention relates to the compounds of formula (I), pharmaceutically acceptable salts, and solvates thereof, wherein the various substituents are as defined herein. The compounds, solvates and salts thereof of Formula (I) are effective as anti-cancer compounds.
Abstract: An electroluminescent device described herein, in one aspect, comprises a first electrode and second electrode and a light emitting layer positioned between the first and second electrodes. A current injection gate is positioned between the first electrode and the light emitting layer or the second electrode and the light emitting layer. In some embodiments, the current injection gate comprises a semiconductor layer of electronic structure restricting injected current flow from the first or second electrode through the semiconductor layer as a function of alternating current voltage frequency applied to the first and second electrodes.
Type:
Grant
Filed:
February 26, 2018
Date of Patent:
November 6, 2018
Assignee:
Wake Forest University
Inventors:
David Carroll, Robert Summers, Yonghua Chen
Abstract: Vascular scaffolds and methods of fabricating the same are disclosed for tissue engineering of vascular constructs. By combining electrospun matrices with cell sheet technologies, vascular constructs with more mature cell layers can be obtained for reconstruction of blood vessels, heart valves and the like. A engineered smooth muscle cell sheet, wrapped around an electrospun vascular scaffold, is able to provide a mature SMC layer that expresses strong cell-to-cell junction markers and contractile proteins. In addition, preconditioning of the cell sheet covered vascular scaffold maintained cell viability and infiltration into the scaffold.
Type:
Grant
Filed:
October 20, 2014
Date of Patent:
October 9, 2018
Assignee:
Wake Forest University Health Sciences
Inventors:
Hyunhee Ahn, Young Min Ju, Anthony Atala, Sang Jin Lee
Abstract: Active compounds useful for inhibiting fatty acid synthase in a subject in need thereof are described. The active compounds are, in general, a 5-mercapto-1H-Indazole-4,7-dione or an analog thereof. The compounds are useful for treating subjects afflicted with, cancer, obesity, diabetes, a viral infection, a bacterial infection, a fungal infection, or a protozoal infection.
Type:
Grant
Filed:
June 27, 2016
Date of Patent:
September 11, 2018
Assignee:
Wake Forest University Health Sciences
Inventors:
Steven J. Kridel, W. Todd Lowther, Herman H. Odens, Jeffrey D. Schmitt
Abstract: Methods and systems for correcting presbyopia using a surgical excimer laser include activating the laser once and transmitting a pre-defined three dimensional ablation profile to treat presbyopia based on the single activating step.
Type:
Grant
Filed:
September 8, 2015
Date of Patent:
August 28, 2018
Assignee:
Wake Forest University Health Sciences
Inventors:
Keith Andrew Walter, Evan Scott Luxon, Christopher Bligh Komanski
Abstract: Newly synthesized thiourea-modified 3-chloro-4-fluoroanilino-quinazoline derivatives have been studied as terminal carrier ligands in linear gold(I) complexes. The molecules mimic the tyrosine kinase inhibitor gefitinib (by computational docking experiments). Thiourea groups were either directly attached to quinazoline-C6 or linked to this position via a flexible ethylamino chain. One compound tested acts as a thiourea-S/quinazoline-N1 mixed-donor ligand, giving an unusual dinuclear complex as determined by X-ray crystallography and/or electrospray mass spectrometry. One compound formed the desired stable linear complex. The biological activity of the carrier ligands and corresponding gold(I) complexes was studied in NCI-H460 and NCI-H1975 lung cancer cells. One compound that was tested partially overcomes resistance to gefitinib in NCI-H1975 (with IC50 values of 1.7 and 30 ?M, respectively), and the corresponding gold complex (13) maintains activity in the low-micromolar concentration range.
Type:
Grant
Filed:
March 15, 2015
Date of Patent:
August 14, 2018
Assignee:
Wake Forest University
Inventors:
Ulrich Bierbach, Mu Yang, Amanda J Pickard
Abstract: The present invention relates to the compounds of formula I, pharmaceutically acceptable salts, and solvates thereof: wherein the various substituents are as defined herein. The compounds, solvates and salts thereof of Formula I are effective as anti-cancer compounds.
Abstract: The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject.
Abstract: The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta. In certain embodiments, the composition comprises amniotic membrane powder or solubilized amniotic membrane (SAM). In some aspects, the composition is cell-free and rich in cytokines, extracellular matrix proteins, and other components that improve tissue regeneration. In one aspect, the composition is a hydrogel scaffold that comprises amniotic membrane. The present invention reduces contraction and improves blood vessel development in regenerating tissue.
Type:
Grant
Filed:
August 1, 2014
Date of Patent:
July 10, 2018
Assignee:
Wake Forest University Health Sciences
Inventors:
Sean V. Murphy, Aleksander Skardal, Anthony Atala
Abstract: Methods of generating an innervated muscle structures are disclosed as well as bioengineered structures for tissue repair or regeneration. The methods can include the steps of obtaining populations of smooth muscle cells and neuronal progenitor cells and then seeding the cells together onto a matrix material, followed by culturing the seeded cells to form an innervated smooth muscle cell construct of directionally oriented smooth muscle cells. In one embodiment, the neuronal progenitor cells can be seeded first as neurospheres in a biocompatible solution, e.g., a collagen/laminin solution, and allowed to gel. Next, a second suspension of smooth muscle cells can be deposited as separate layer. Multiple layer structures of alternating muscle or neuron composition can also be formed in this manner. Differentiation of the neuronal progenitor cells can be induced by exposure to a differentiation medium, such as Neurobasal A medium and/or exposure to a differentiating agent, such as B-27 supplement.